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To identify and characterize myeloid cell populations within the CSF of patients with MS and
anti-myelin oligodendrocyte glycoprotein (MOG) disorder by high-resolution single-cell gene
expression analysis.
Methods
Single-cell RNA sequencing (scRNA-seq) was used to profile individual cells of CSF and blood
from 2 subjects with relapsing-remitting MS (RRMS) and one with anti-MOG disorder.
Publicly available scRNA-seq data from the blood and CSF of 2 subjects with HIV were also
analyzed. An informatics pipeline was used to cluster cell populations by transcriptomic pro-
filing. Based on gene expression by CSF myeloid cells, a flow cytometry panel was devised to
examine myeloid cell populations from the CSF of 11 additional subjects, including individuals
with RRMS, anti-MOG disorder, and control subjects without inflammatory demyelination.
Results
Common myeloid populations were identified within the CSF of subjects with RRMS, anti-
MOG disorder, and HIV. These included monocytes, conventional and plasmacytoid dendritic
cells, and cells with a transcriptomic signature matching microglia. Microglia could be dis-
criminated from other myeloid cell populations in the CSF by flow cytometry.
Conclusions
High-resolution single-cell gene expression analysis clearly distinguishes distinct myeloid cell
types present within the CSF of subjects with neuroinflammation. A population of microglia
exists within the human CSF, which is detectable by surface protein expression. The function of
these cells during immunity and disease requires further investigation.
*These authors contributed equally to this work.
From the Department of Pathology and Immunology (E.E., I.S., K.Z., G.F.W., M.N.A., B.T.E.) and Department of Neurology (C.C., R.C.B., G.F.W., A.H.C.), Washington University School of
Medicine, St. Louis, MO; and Computer Technologies Department (K.Z.), ITMO University, St. Petersburg, Russia.
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
The Article Processing Charge was funded by the NIH, NMSS, and ICTS.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading
and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. 1
CSF evaluation is used to aid in the diagnosis and differentia-
tion of CNS disorders. In inflammatory CNS diseases, the CSF
is typically used to assess the immunopathophysiologic pro-
cesses because biopsy of CNS tissue carries significant potential
for harm.1 However, relatively few cells are obtained from CSF,
usually on the order of 1–5 cells/μL. Recent refinements in
next-generation sequencing have enabled the efficient de-
termination of individual cell gene expression within bio-
specimens with relatively sparse cell populations, such as the
CSF. Patterns identified using single-cell RNA sequencing
(scRNA-seq) can uncover distinct cell types present at low
levels within cellular communities and tissues.2 scRNA-seq was
used to assess inflammatory changes within the CSF of subjects
with HIV infection, identifying the presence of a “microglial-
like” cell,3 and more recently to explore the clonal expansion of
CSF lymphocytes in MS-discordant monozygotic twin pairs.4
scRNA-seq has also been used to address the issue of microglial
heterogeneity within the human brain.5–7 In addition, using the
primary animal model of MS, experimental autoimmune en-
cephalomyelitis, scRNA-seq has been used to identify several
populations of myeloid cells, both endogenous to the CNS and
from peripheral blood.8 New methods for characterization of
myeloid populations within the CNS during disease offer the
opportunity to dissect the origin, function, and pathogenicity of
each cell type with much greater resolution than previous
methods.
MS is the most common inflammatory demyelinating disease
of the CNS, affecting over 600,000 people in the United
States.9 Anti-myelin oligodendrocyte glycoprotein (MOG)
disorder is a newly described CNS demyelinating disease that
shares clinical and pathologic characteristics with MS.10,11 MS
and anti-MOG disorder appear to be distinct from one an-
other and from aquaporin 4 antibody-positive neuromyelitis
optica (NMO).10,12 We have applied scRNA-seq to examine
the CSF and mononuclear cells of the peripheral blood of
subjects with relapsing-remitting MS (RRMS) and anti-MOG
disorder. Individual spinal fluid samples from 2 subjects with
RRMS and 1 subject with anti-MOG disorder were analyzed
by using scRNA-seq. In all 3 subjects, we uncovered CSF
populations of immune cells including microglial cells, mon-
ocytes, and dendritic cells (DCs) based on gene expression.
Using CSF and blood from 7 additional subjects with RRMS,
another subject with anti-MOG disorder, and 3 control sub-
jects, we designed and tested a flow cytometry strategy that
confirmed the presence in CSF of these cell types.
Methods
Subjects
Eleven subjects with inflammatory demyelinating disease (9
with RRMS and 2 with anti-MOG disorder) and 3 control
subjects (1 with amyotrophic lateral sclerosis [ALS], 1 with
idiopathic intracranial hypertension [IIH], and 1 healthy control
[HC]) were recruited for a study to assess the characteristics of
CSF and blood cells (table). The institutional review board of
Washington University in St. Louis approved study protocols,
and each subject provided informed consent. Nine subjects had
RRMS based on the current diagnostic criteria.13 Two addi-
tional subjects were diagnosed with anti-MOG disorder: one
presented with optic neuritis and the other with partial trans-
verse myelitis. Anti-MOG disorder was diagnosed based on the
6-month sustained positive cell-based assays for MOG IgG1
antibody, absence of antibodies to aquaporin 4 (NMO-IgG),
and absence of CSF-restricted oligoclonal bands.11
To prevent alterations because of disease-modifying therapies, we
selected subjects either on no therapy or remote from therapy.
Seven subjects with RRMS were naive to therapy, including cor-
ticosteroids. Of the remaining 2 subjects with RRMS, 1 (subject 7)
had received fingolimod, stopping 9 months before CSF testing,
and the other (subject 10) was treated with glatiramer acetate for 5
months and had received IV steroids 2 months before CSF anal-
ysis.The subjectwith transversemyelitis due to anti-MOGdisorder
(subject 8) had receivedmycophenolate and then azathioprine but
had discontinued these 6 months before CSF analysis and had
received a course of corticosteroids 4 months before CSF exami-
nation. Subject 1 with anti-MOG disorder had received no treat-
ment before the examination of CSF. Control specimens were
obtained from a subject with IIH who presented with visual dis-
turbances, a patient diagnosed with ALS, and a HC. Each con-
tributed blood and CSF cells for scRNA-seq or flow cytometry
studies (table and figure e-1, links.lww.com/NXI/A244).
Standard protocol approvals, registrations,
and patient consents
Informed consent was obtained from all participants and
approved by the Human Research Protection Office of
Washington University in St. Louis.
CSF and peripheral blood mononuclear
cell preparation
CSF was collected in a 50-mL conical tube on ice and
centrifuged for 10 minutes at 400g. Supernatant was removed
Glossary
AD = Alzheimer disease; ALS = amyotrophic lateral sclerosis; BAM = border-associated macrophage; CCA = canonical
correlation analysis; cDC = conventional DC;DAM = disease-associated microglia;DC = dendritic cell;HC = healthy control;
HLA-DR = human leukocyte antigen DR; IIH = idiopathic intracranial hypertension; MOG = myelin oligodendrocyte
glycoprotein;NMO = neuromyelitis optica; PBMC = peripheral blood mononuclear cell; PCA = principal component analysis;
pDC = plasmacytoid DC; RRMS = relapsing-remitting MS; scRNA-seq = single-cell RNA sequencing; UMAP = Uniform
Manifold Approximation and Projection.
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without disrupting the cell pellet, which was resuspended in
400 μL of PBS containing 0.04% bovine serum albumin. The
CSF cells were counted with a hemocytometer and resus-
pended in a volume of PBS/0.04% bovine serum albumin to
achieve a cell concentration of 700–1,000 cells/μL for scRNA-
seq. Peripheral blood mononuclear cells (PBMCs) were iso-
lated by Ficoll density centrifugation and then processed
alongside CSF cells for scRNA-seq or flow cytometry.
Flow cytometry
Flow cytometry analysis was performed using antihuman
antibodies to BDCA-2 (clone 201A; BioLegend, San Diego,
CA), CD33 (clone P67.6; BioLegend), CD14 (clone 61D3;
eBioscience, San Diego, CA), Lyve-1 (clone 537028; R&D
Systems, Minneapolis, MN), CD3 (clone SK7; BioLegend),
CD19 (clone HIB19; eBioscience), CD16 (clone B73.1;
BioLegend), CD1c (clone L161; BioLegend), Lox-1 (clone
15C4; BioLegend), and human leukocyte antigen DR (HLA-
DR) (clone Immu-357; Beckman Coulter, Brea, CA). One
million PBMCs and between 2 × 104 and 40 × 104 CSF cells
were incubated with human-Fc block (BD Biosciences, San
Jose, CA) for 10 minutes at RT and then with antibodies for
20 minutes at 4°C. Subsequently, the samples were washed
with PBS + 2% FBS (flow buffer) for 59, spun at 500g, and
resuspended in 200 μL of flow buffer. The samples were run
on a Gallios flow cytometer (Beckman Coulter Life Sciences)
on the same day of the collection. The cells were analyzed
using FlowJo software (Tree Star, Ashland, OR).
RNA sequencing and analysis
On the day of cell collection using fresh cells, droplet-based 39
(for anti-MOG disorder subject 1) and 59 (for subjects 2 and
5 with RRMS) libraries were prepared using Chromium
Single Cell 39 v2 or 59 Reagent Kits according to the manu-
facturer’s protocol from 10× Genomics. The generated
scRNA libraries were sequenced using an Illumina HiSeq4000
or Novaseq sequencer. Cell Ranger Single-Cell Software 2.2
was used to perform sample demultiplexing, barcode pro-
cessing, and single-cell 39 and 59 counting. Afterward, fastq
files for each sample were processed with a cellranger count,
which was used to align the samples to GRCh38 genome,
filter, and quantify reads. For each sample, the recovered-cells
parameter was specified as 10,000 cells that we expected to
recover for each individual library.
To reanalyze scRNA-seq data performed with SeqWell publicly
available from GSE117397, we downloaded count tables from 2
subjects with HIV for whom both CSF and blood samples were
available from GEO DataSets (GSM3293822, HIV1_Bld;
GSM3293823, HIV1_CSF; GSM3293824, HIV2_Bld;
GSM3293825, HIV2_CSF). To combine data from all samples
together, we used the canonical correlation analysis (CCA) al-
gorithm from Seurat 3.14 Before applying CCA, we removed
cells from the 39 and 59 data sets that contain more than 10% of
mitochondrial RNA. Cells from SeqWell data sets with less than
20% of RNA from mitochondrial genes and more than 500 but
less than 2,500 expressed genes were considered viable cells.
Table Demographic and clinical characteristics of subjects
Subject Age, y Sex Race Diagnosis Presentation at onset
Time from symptom
onset to LP CSF OCB Analysis
1 56 F Caucasian Anti-MOG disorder ON OD and paresthesias 8 mo 0 scRNA-seq
2 38 F Caucasian RRMS ON OD 6 wk 3 scRNA-seq
3 53 F Caucasian RRMS Paresthesias 3 y 13 Flow cytometry
4 23 F Caucasian RRMS ON OD 4 mo 7 Flow cytometry
5 34 F Caucasian RRMS ON OD 2 y 11 scRNA-seq
6 40 F Caucasian RRMS Paresthesias and tremor 15 mo 5 Flow cytometry
7 41 F Caucasian RRMS ON OS 12 y 9 Flow cytometry
8 22 M Caucasian Anti-MOG disorder Paresthesias and leg weakness 2 y 0 Flow cytometry
9 45 M Caucasian RRMS Lhermitte sign 6 mo 7 Flow cytometry
10 38 F Caucasian RRMS ON OS 6 mo 10 Flow cytometry
11 38 F Caucasian IIH TVO 1 y 0 Flow cytometry
12 70 M Caucasian ALS Weakness 4 y N/D Flow cytometry
13 45 M Caucasian HC N/A N/A N/D Flow cytometry
14 40 M Caucasian RRMS Right-sided weakness 3 mo 4 Flow cytometry
Abbreviations: ALS = amyotrophic lateral sclerosis; HC = healthy control; IIH = idiopathic intracranial hypertension; OD = oculus dextra (right eye); ON = optic
neuritis; OS = oculus sinistra (left eye); LP = lumbar puncture with CSF analysis; MOG = myelin oligodendrocyte glycoprotein; N/A = not applicable; N/D = not
done; OCB = oligoclonal band; RRMS = relapsing-remitting MS; scRNA-seq = single-cell RNA sequencing; TVO = transient visual obscuration.
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After CCA data were scaled, principal component analysis
(PCA) was performed with RunPCA function. A Uniform
Manifold Approximation and Projection (UMAP) di-
mensionality reduction was performed on the scaled matrix
using the first 20 PCA components to obtain a 2-dimensional
representation of the cell states.15 For clustering, we used
FindNeighbours and FindClusters functions on 20 PCA
components with a resolution of 0.5. FindAllMarkers function
was used to characterize clusters. For heatmap representation,
the mean expression of markers inside each cluster was used.
Heatmaps were built with Phantasus software (artyomovlab.
wustl.edu/phantasus/).
Data availability
Anonymized scRNA-seq is available to qualified investigators
at synapse.org (syn21904732).
Results
Discrete immune cell populations can be
identified in the CSF and blood of subjects with
neuroinflammatory diseases using scRNA-seq
To explore the extent, diversity, and phenotype of leukocyte
infiltration into the CNS compartment during CNS de-
myelination, we performed scRNA-seq of CSF cells and
PBMCs from 1 subject with anti-MOG disorder (subject 1)
and 2 subjects with RRMS (subjects 2 and 5). During the
course of our data collection, scRNA-seq of immune cells
isolated from the blood and CSF of subjects with HIV was
reported.3 Given the small number of data sets on CSF,
a difficulty to access tissue, we sought to optimally identify
populations of immune cells reflective of neuroinflammation
using a recently described computational method, CCA, that
allows integration across different scRNA-seq technologies.14
Applying this method, data from a total of 23,363 PBMCs and
14,179 CSF cells were combined and visualized using the
UMAP technique15 and unsupervised clustering.16,17
Twenty clusters representing distinct cell populations were
identified (figure 1A). We used the characteristic marker gene
expression to assign cellular identities to each cluster (figure
1B). Several distinct lymphoid cell clusters, including CD8+
T cells, CD4+ T cells, γδ T cells, NK cells, and B cells, could be
discriminated in both PBMCs and CSF. Myeloid populations
were also identified, including microglia, CD14+ and CD16+
monocytes, and 2 distinct groups of DCs—plasmacytoid
(pDCs) and conventional (cDCs). Examining each subject
individually, there were nomeaningful disparities in cell clusters
between the subjects (figure e-2, links.lww.com/NXI/A244).
We also compared the proportional abundance of specific cell
clusters within either the CSF or blood (figure 1C). We
identified a cluster of cells that exhibited features of cell stress,
including expression of the mitochondrial genes MTRNR2L8
and MTRNRL12, which are indicative of low quality or dying
cells (labeled “Dead” in figure 1).7 These dead cells, as well as
red blood cells and platelets, were found almost solely within
the blood. Similarly, we observed one population of NK cells
(NK_1) that was exclusively present in the blood. This pop-
ulation shows a gene expression profile matching the recently
defined blood NK1 cells, which align with previously described
CD56dim NK cells (figure e-3, links.lww.com/NXI/A244).18
Among the T and B cell clusters, several exist in higher
abundance in the blood (naive CD8, CD8_2, CD8_3, naive
CD4, γδ T cells, and B_cells_1). CD14+ and CD16+ mon-
ocytes were more prevalent in blood than CSF, with the latter
being entirely absent from the CSF. cDCs were a smaller
fraction among PBMC relative to CSF cells, whereas pDCs
were found in both compartments in similar proportions.
Microglia were exclusively found in the CSF. Given the
complexity of cells with myeloid characteristics in neuro-
inflammatory diseases and the historic difficulty of studying
these cells in CSF by conventional methods because of limited
cell numbers, we dedicated subsequent analyses of our data to
CSF myeloid cell populations.
CSF microglia and other myeloid cell types
in neuroinflammation
Analyzing the genes expressed by the cluster of CSF cells that
we term microglia revealed high expression of genes from the
microglial homeostatic gene signature, including CX3CR1,
CSF1R, SLC2A5, MARCKS, and P2RY13 (figure 2A).7,19,20
Recent scRNA-seq analyses of human brain microglia have
defined heterogeneity among microglia.6,7 Sankowski et al.7
defined 8 clusters of human brain microglia (termed C1–C3,
C5–C9) with differential gene expression among these clus-
ters. Expression of these microglia cluster-specific genes
across the myeloid cell populations from our scRNA-seq
composite data set was next examined. Many of these genes
were found to be strikingly microglia-specific, including
APOC1, APOE, LYVE1, TREM2, C1QB, GPR34, OLR1, and
C3 (figure 2B). Sankowski et al. also created a classifier tool to
discriminate microglial clusters, which they successfully ap-
plied to publicly available scRNA-seq data sets of brain
microglia. When we applied this classifier to the 394 CSF cells
in our data set that were grouped as microglia, 88% of these
were classified as belonging to C6, with 10% belonging to C7.
C6 and C7 were characterized by Sankowski et al. as having
high expression of genes in the Gene Ontology pathway
0048002 (“antigen processing and presentation of peptide
antigen”). In sum, these data strongly support our conclusion
that the myeloid cell populations we find exclusively in the
CSF are microglial cells and suggest that they may be involved
in antigen presentation.
Two previous studies using scRNA-seq to classify CSF
immune cells, each identified a discrete cell population
that was categorized as either “microglia-like” cells3 or
“monocytes.”4 Each study produced a list of genes that
discriminated these differently named clusters from other
CSF immune cells. When we visualized these gene sets
among the clusters of CSF cells in our composite data set,
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which includes a reanalysis of the cells from 2 subjects in-
cluded in the work of Farhadian et al., we found markedly
enriched expression in the cluster that we term microglia
(figure 2C). With this, we mean that all 3 studies are in fact
referring to the same subset of CSF cells, and given their
expression of core microglial genes, we prefer to classify
these as microglia.
Other myeloid populations could also be distinctly classified by
their transcriptional profiles. Figure 3 is a heatmap of the ex-
pression of 10 genes per cell type, which discriminated each
myeloid population. Some of these genes were known to dis-
criminate myeloid cell types, yet others are new and could be
revealing different classifiers. Notably, expression of major
histocompatibility complex class II genes was higher in CSF
cDCs than blood cDCs, possibly indicating a compartmental
influence on the antigen presentation function of these cells.
These transcriptomic data establish the presence of one
monocyte subset, 2 types of DCs, andmicroglia within the CSF
during neuroinflammation.
Flow cytometric characterization of CSF cells
validates scRNA-seq identification of microglia
and myeloid cell types
We sought to create a flow cytometric-based strategy for the
quantification of various CSF myeloid cell types, including
microglia, using commercially available antibodies specific for
surface markers identified by our gene expression studies
Figure 1 scRNA-seq characterization of leukocytes from MS, anti-MOG disorder, and HIV
(A) UMAP of immune cell clusters from the blood (top) and CSF (bottom) of all subjects merged. (B) Characteristic marker gene expression assigned to each
cluster displayed by UMAP. (C) Proportional abundance of 20 cell clusters within the blood (purple) and CSF (yellow). Y axis represents the percentage of all
cells. cDC = conventional DC; PBMC = peripheral blood mononuclear cell; pDC = plasmacytoid DC; RBC = red blood cell; Tgd = γδ T cells; UMAP = Uniform
Manifold Approximation and Projection.
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(figure e-4, links.lww.com/NXI/A244) and the literature.21
PBMCs and CSF cells were stained for CD3 and CD19 to
gate out T and B cells. Within the remaining cells in both CSF
and blood, pDCs were identified as being HLA-DR+ and
BDCA-2+ (encoded by CLEC4C), whereas cDCs were
identified as HLA-DR+BDCA-2−CD1c+ cells (figure 4A). In
the CSF, non-DCs could be seen to resolve as 2 distinct cell
types based on the HLA-DR and CD33 levels. PBMCs only
contained HLA-DRmidCD33high cells, which were defined as
monocytes. The CSF additionally contained a population of
HLA-DRhighCD33mid cells, which we interpreted as microglia,
further confirmed by their expression of Lyve-1 and Lox-1
(encoded byOLR1). CSF from subjects with other neurologic
conditions (anti-MOG disorder, ALS, and IIH) and a HC
subject also contained similarly staining populations of pDCs,
cDCs, monocytes, and microglia (figure 4B). The staining
intensity of HLA-DR, CD33, Lyve-1, and Lox-1 discriminated
CD14+ monocytes from microglia in the CSF of all subjects
(figure 4C). Overall, flow cytometric characterization of my-
eloid cells demonstrated the protein expression of various
microglial genes identified by transcriptomic profiling, con-
firmed the presence of microglia within the CSF, and offered
a ready means for identifying this cell type.
Discussion
We performed scRNA-seq to identify the cell types present
within the CSF of 2 subjects with RRMS and 1 person with
anti-MOG disorder, with comparative analysis to paired
PBMCs. These and subsequent subjects were not taking
disease-modifying therapies or corticosteroids. Subsequently,
we integrated publicly available data on 2 subjects with HIV
on whom scRNA-seq was performed on paired PBMCs and
CSF immune cells. We then focused on CSF myeloid cell
types because less work has been carried out to characterize
these populations in part because of their lower abundance.
We found that (1) scRNA-seq identifies a diverse set of my-
eloid cell types within the CSF, including microglia; (2) flow
cytometry is a feasible technique for the discrimination of
these populations of CSF myeloid cells; and (3) scRNA-seq
data can be integrated across technologies to allow for optimal
discrimination of cell populations.
Because the data sets we analyzed were derived from different
technologies, we used a recently described technique, CCA, to
integrate scRNA-seq data sets. This allowed for an increased
number of cells used in the analysis, facilitating the optimal
discrimination of cell clusters. All CSF samples in the combined
analysis contained cells within each cluster, suggesting that
among the diseases examined herein, a common set of leuko-
cytes inhabit this critical immune space within the CNS. One
limitation of CCA involves the exclusion of some genes from
downstream analysis. Nevertheless, in our case, 2,000 genes
were still available for use in our assessment of PBMCs and
CSF cells from 5 individuals. Our results demonstrate the
feasibility of using CCA to integrate the growing number of
scRNA-seq data sets that will continue to be made publicly
available using different platforms.
Our scRNA-seq analysis identified microglia in human CSF
with a gene expression pattern overwhelmingly similar to
that described for parenchymal microglia.7,19,22,23 We used
genes from a recent study describing the transcriptional
profile of human tissue-resident microglia as a comparison
for the CSF microglia identified in our subjects.7 The top
genes identified in tissue-resident microglia were also highly
abundant in our CSF microglia populations (figure 2).
Owing to their low abundance in the CSF, this subset of cells
has apparently been overlooked in most previous CSF
studies using less powerful techniques. One previous report
using a different scRNA-seq platform, SeqWell, also identi-
fied this population of cells in human CSF and termed them
“microglia-like.”3 Our reanalysis of the published data from
the latter study confirmed the presence of cells expressing
hallmark microglial genes and lacking expression of genes
that identify other myeloid cell types. A more recently
published study involving patients with MS also identified
several distinct myeloid cell types within the CSF.24 Based
on the analysis of our data, we believe this group used the
term “Mono2” in reference to a population encompassing
CSF microglia. Indeed, they describe a subset of monocytes
that expressed microglial-associated genes, including
TREM2, TMEM119, and GPR34, and concluded that these
cells share features with both border-associated macro-
phages (BAMs), which have been ascribed immunoregula-
tory functions within the CNS,22 and homeostatic microglia.
In the future, it will be important to devise nomenclature
which prudently encompasses the appropriate degree of
segregation among various myeloid cell populations. In
particular, BAMs share substantial transcriptional overlap
with microglia,25 prompting the consideration of how CSF
microglia differ in ontogeny and function from BAMs that
will need to be resolved with further investigation into the
ontogeny and function of each cell type.
Microglia are long-lived, self-replicating, yolk sac-derived
immune cells of the CNS parenchyma involved in CNS
development and neuropathology.26,27 Disruption of the
blood-brain barrier can allow the replacement of microglia by
blood-derived progenitors, with the latter eventually taking on
the near-complete gene expression profile of fetal-derived
microglia.28 Our studies of CSF microglia cannot determine
their ontogeny or how they gained access to the CSF.
Microglia from the CNS parenchyma might traverse the pia
mater or choroid plexus or traffic into CSF through peri-
vascular spaces or via lymphatic drainage.29,30 Migration of
parenchymal microglia or blood-derived progenitor cells that
become microglia may occur in response to chemokines,
which is supported by our finding of chemokine receptors on
these cells, including CCR1, CCR5, CXCR4, and CX3CR1. It
is also possible that a unique microglial subset exists that
develops and permanently resides in the CSF. CSF microglia
also may not be singular in origin.31
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Figure 2 Relative expression of myeloid population-defining genes in neuroinflammation
(A) Expression of canonical microglial genes within the UMAP of CSF immune cell clusters. (B) Heatmap representation of gene expression in blood (purple)
and CSF (yellow) myeloid populations. Gene list derived from Sankowski et al.7 (C) Top genes reported by Farhadian et al.3 as specific for “microglia-like cells”
(top) and Beltran et al.4 as specific for “monocytes” (bottom) displayed in the UMAP of immune cell clusters in the CSF of all subjects. cDC = conventional DC;
PBMC = peripheral blood mononuclear cell; pDC = plasmacytoid DC; UMAP = Uniform Manifold Approximation and Projection.
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The source of CSF microglia may have functionally relevant
implications. Microglia are known to be critical modulators of
CNS developmental processes, such as synaptic pruning.32,33
Recent data reveal the subsets of microglia with distinct
functions. In the scRNA-seq analysis of rodent CNS, BAMs
and other myeloid populations have been identified within
Figure 3 Discrimination of myeloid cell populations in neuroinflammation by gene expression
Heatmap of 10 genes that discriminate myeloid cell types within the blood (purple) and CSF (yellow). Columns represent individual subjects. cDC = con-
ventional DC; PBMC = peripheral blood mononuclear cell; pDC = plasmacytoid DC.
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Figure 4 Flow cytometric identification of microglia and myeloid cells within the blood and CSF
(A andB) Plots were obtained by gating on CD3−CD19− singlets. HLA-DR+BDCA-2hi cells represent pDCs. cDCs are represented asHLA-DR+BDCA-2−CD1chi. Red
gates in the third column represent microglia, whereas blue gates represent monocytes. The fourth column shows HLA-DR and Lyve-1 staining of microglia
(red) andmonocytes (blue). The fifth column shows HLA-DR and Lox-1 staining of microglia (red) andmonocytes (blue). (A) Flow cytometry on CSF and blood
samples from a subject with RRMS. (B) Flow cytometry on CSF from subjects with anti-MOG disorder (anti-MOG), ALS, IIH, and a healthy control. (C) Mean
fluorescence intensity (MFI) of HLA-DR, CD33, Lyve-1, and Lox-1 of CSFmonocytes andmicroglia from subjects. Each pair of connected circles represents one
CSF sample. Statistical significance was determined using a paired Student t test. ALS = amyotrophic lateral sclerosis; cDC = conventional DC; IIH = idiopathic
intracranial hypertension; MOG = myelin oligodendrocyte glycoprotein; PBMC = peripheral blood mononuclear cell; pDC = plasmacytoid DC.
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brain, choroid plexus, and leptomeningeal tissue at steady-
state and in the experimental autoimmune encephalomyelitis
model of MS.8 Studies using animal models for Alzheimer
disease (AD) have identified a phagocytic subset of microglia
termed “disease-associated microglia” (DAM).23 DAM ap-
pear to reduce disease severity in the model and express genes
associated with AD such as Apoe and Trem2. In addition,
homeostatic microglia and a subpopulation transitioning be-
tween homeostatic microglia and DAM were identified in
mouse AD models. Experiments such as these in mice high-
light not only the high resolution of CNS myeloid cell sub-
types that can be obtained using scRNA-seq but also the
apparent dynamic nature of myeloid populations.
Using a flow cytometric panel with commercially available
reagents, our data demonstrated the protein expression of some
of the microglial genes identified by RNA and indicate that
microglia range from 0.2% to 5.5% of CSF mononuclear cells.
Overall, the presence of microglia within the CSF was not
disease-dependent or disease-activity dependent because they
were detected in theCSF of a healthy subject as well as in subjects
with noninflammatory neurologic diseases (IIH, ALS) and in 2
distinct neuroinflammatory diseases (MS and anti-MOG disor-
der). Comparison of CSF microglial frequencies between dis-
eases could not be performed because of low cell numbers. It is
possible that subtle differences in the numbers or subtypes of
CSF microglia could reflect the state of disease in MS or other
diseases. Neither of the subjects with RRMS nor the subject with
anti-MOG disorder analyzed for our study was undergoing acute
relapse, which may have influenced the presence or number of
CSF microglia. Our data demonstrate the feasibility of using
standardflow cytometry in the future to address the association of
CSF myeloid populations, including CSF microglia, with the
clinical state of inflammatory demyelination within the CNS.
cDCs and pDCs were each identified in CSF by both scRNA-
seq and flow cytometry. Previous studies have identified these
cell types in CSF using lower resolution flow cytometry with
fewer markers for discrimination of these myeloid populations
and have reported an increased number of pDCs in the CSF
during MS relapses.21,34 Recent scRNA-seq analysis examined
DCs and monocytes in human blood, identifying 6 discrete
subsets of blood DCs, including 4 subsets of cDCs, a subset of
classical pDCs, and a new subset termedAXL+SIGLEC6+ (AS)
DCs.35 ScRNA-seq analysis of the samples in our study did not
result in discrete clusters of DC subsets in the blood or CSF,
perhaps owing to their low abundance. A dedicated scRNA-seq
study focused on sorted CSFDCs would likely reveal additional
heterogeneity in these populations. More importantly, our
analyses of differentially expressed genes between cDCs in the
CSF compared with cDCs in the blood reveal that these pop-
ulations, although still fundamentally cDCs, may alter some of
their gene expression based on their microenvironment. In-
terestingly, those genes thatmost discriminatedCSF cDCswere
more highly expressed by CSF microglia, whereas those that
discriminated blood cDCsweremore highly expressed by blood
monocytes. These results suggest that environmental signals
may result in shared tissue-specific gene expression patterns
across myeloid cell populations.
Using gene expression-based methods to categorize cell types,
we identified microglia, monocytes, cDCs, and pDCs within
the CSF. The recognition that microglia are present in CSF
may have important clinical implications. Abnormally func-
tioningmicroglia are believed to contribute to the pathogenesis
and/or regulation of several diseases, including AD and MS.
Our results indicate that it may be possible to analyzemicroglial
abnormalities directly from the CSFwithout requiring biopsies.
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7. Sankowski R, Böttcher C, Masuda T, et al. Mapping microglia states in the human
brain through the integration of high-dimensional techniques. Nat Neurosci 2019;22:
2098–2110. doi: 10.1038/s41593-019-0532-y.
8. Jordão MJC, Sankowski R, Brendecke SM, et al. Neuroimmunology: single-cell
profiling identifies myeloid cell subsets with distinct fates during neuroinflammation.
Science 2019;363:eaat7554. doi: 10.1126/science.aat7554.
9. Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United
States: a population-based estimate using health claims data. Neurology 2019;92:
e1029–e1040. doi: 10.1212/WNL.0000000000007035.
10. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein anti-
bodies in adults with a neuromyelitis optica phenotype. Neurology 2012;79:
1273–1277. doi: 10.1212/WNL.0b013e31826aac4e.
11. Kim SM, Woodhall MR, Kim JS, et al. Antibodies to MOG in adults with in-
flammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm
2015;2:e163. doi: 10.1212/NXI.0000000000000163.
12. Hyun JW, Huh SY, Shin HJ, et al. Evaluation of brain lesion distribution crite-
ria at disease onset in differentiating MS from NMOSD and MOG-IgG-
associated encephalomyelitis. Mult Scler J 2019;25:585–590. doi: 10.1177/
1352458518761186.
13. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017
revisions of the McDonald criteria. Lancet Neurol 2018;17:162–173. doi: 10.1016/
S1474-4422(17)30470-2.
14. Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell tran-
scriptomic data across different conditions, technologies, and species. Nat Biotechnol
2018;36:411–420. doi: 10.1038/nbt.4096.
15. Becht E, McInnes L, Healy J, et al. Dimensionality reduction for visualizing
single-cell data using UMAP. Nat Biotechnol 2019;37:38–47. doi: 10.1038/nbt.
4314.
16. Amir EAD, Davis KL, Tadmor MD, et al. ViSNE enables visualization of high di-
mensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat
Biotechnol 2013;31:545–552. doi: 10.1038/nbt.2594.
17. Van DerMaaten L, Hinton G. Visualizing data using t-SNE. JMach Learn Res 2008;9:
2579–2625.
18. Crinier A, Milpied P, Escalière B, et al. High-dimensional single-cell analy-
sis identifies organ-specific signatures and conserved NK cell subsets in
humans and mice. Immunity 2018;49:971–986.e5. doi: 10.1016/j.immuni.
2018.09.009.
19. Butovsky O, Jedrychowski MP, Moore CS, et al. Identification of a unique TGF-
β-dependent molecular and functional signature in microglia. Nat Neurosci 2014;17:
131–143. doi: 10.1038/nn.3599.
20. Gautier EL, Shay T, Miller J, et al. Gene-expression profiles and transcriptional reg-
ulatory pathways that underlie the identity and diversity of mouse tissue macrophages.
Nat Immunol 2012;13:1118. doi: 10.1038/ni.2419.
21. Pashenkov M, Huang YM, Kostulas V, Haglund M, Söderström M, Link H. Two
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30. Ransohoff RM, Kivisäkk P, Kidd G. Three or more routes for leukocyte migration into
the central nervous system. Nat Rev Immunol 2003;3:569–581. doi: 10.1038/nri1130.
31. Li Q, Cheng Z, Zhou L, et al. Developmental heterogeneity of microglia and brain
myeloid cells revealed by deep single-cell RNA sequencing. Neuron 2019;101:
207–223.e10. doi: 10.1016/j.neuron.2018.12.006.
32. Schafer DP, Lehrman EK, Kautzman AG, et al. Microglia sculpt postnatal neural
circuits in an activity and complement-dependent manner. Neuron 2012;74:691–705.
doi: 10.1016/j.neuron.2012.03.026.
33. Paolicelli RC, Bolasco G, Pagani F, et al. Synaptic pruning by microglia is necessary for
normal brain development. Science 2011;333:1456–1458. doi: 10.1126/science.
1202529.
34. Longhini ALF, von Glehn F, Brandão CO, et al. Plasmacytoid dendritic cells are
increased in cerebrospinal fluid of untreated patients during multiple sclerosis relapse.
J Neuroinflammation 2011;8:2. doi: 10.1186/1742-2094-8-2.
35. Villani A-C, Satija R, Reynolds G, et al. Single-cell RNA-seq reveals new types of









Data acquisition and analysis;
drafting of text and figures; revised








Study concept and design; data
acquisition and analysis; drafting of
the text and figures; revised the


























Study concept and design; data
acquisition and analysis; drafting of
the text and figures; revised the







Study concept and design; data
acquisition and analysis; revised the






Study concept and design; data
acquisition and analysis; drafting of
the text and figures; revised the







Study concept and design; data
acquisition and analysis; drafting of
the text and figures; revised the
manuscript for intellectual content
Neurology.org/NN Neurology: Neuroimmunology & Neuroinflammation | Volume 7, Number 4 | July 2020 11
DOI 10.1212/NXI.0000000000000732
2020;7; Neurol Neuroimmunol Neuroinflamm 
Ekaterina Esaulova, Claudia Cantoni, Irina Shchukina, et al. 
neuroinflammation
Single-cell RNA-seq analysis of human CSF microglia and myeloid cells in
This information is current as of May 5, 2020
Academy of Neurology.. All rights reserved. Online ISSN: 2332-7812.
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American
Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright 




including high resolution figures, can be found at:
References
 http://nn.neurology.org/content/7/4/e732.full.html##ref-list-1
This article cites 35 articles, 6 of which you can access for free at: 
Citations
 http://nn.neurology.org/content/7/4/e732.full.html##otherarticles









All Demyelinating disease (CNS)
following collection(s): 




its entirety can be found online at:




Information about ordering reprints can be found online:
Academy of Neurology.. All rights reserved. Online ISSN: 2332-7812.
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American
Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright 
is an official journal of the American Academy of Neurology.Neurol Neuroimmunol Neuroinflamm 
